Topical calcineurin inhibitors

Mark G. Lebwohl; Chrystal A. Landry

Topical calcineurin inhibitors

Mark G. Lebwohl
, Chrystal A. Landry

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Topical calcineurin inhibitors are a treatment option for individuals with certain limited manifestations of psoriasis. While these immunomodulatory drugs were initially developed for preventing organ rejection in transplant patients, they have quickly become a mainstay of off-label treatment for psoriasis since their clinical introduction in topical formulation in 2000. The topical calcineurin inhibitors tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream are approved for treatment of atopic dermatitis in the United States.

Original language	English
Title of host publication	Mild-to-Moderate Psoriasis, Second Edition
Publisher	CRC Press
Pages	83-90
Number of pages	8
ISBN (Electronic)	9781420088618
ISBN (Print)	9781420088601
State	Published - 1 Jan 2008

Cite this

@inbook{4cd07a6fe5614b7ba2e593bd9535d1f4,

title = "Topical calcineurin inhibitors",

abstract = "Topical calcineurin inhibitors are a treatment option for individuals with certain limited manifestations of psoriasis. While these immunomodulatory drugs were initially developed for preventing organ rejection in transplant patients, they have quickly become a mainstay of off-label treatment for psoriasis since their clinical introduction in topical formulation in 2000. The topical calcineurin inhibitors tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream are approved for treatment of atopic dermatitis in the United States.",

author = "Lebwohl, \{Mark G.\} and Landry, \{Chrystal A.\}",

note = "Publisher Copyright: {\textcopyright} 2009 by Informa Healthcare USA, Inc.",

year = "2008",

month = jan,

day = "1",

language = "English",

isbn = "9781420088601",

pages = "83--90",

booktitle = "Mild-to-Moderate Psoriasis, Second Edition",

publisher = "CRC Press",

}

TY - CHAP

T1 - Topical calcineurin inhibitors

AU - Lebwohl, Mark G.

AU - Landry, Chrystal A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Topical calcineurin inhibitors are a treatment option for individuals with certain limited manifestations of psoriasis. While these immunomodulatory drugs were initially developed for preventing organ rejection in transplant patients, they have quickly become a mainstay of off-label treatment for psoriasis since their clinical introduction in topical formulation in 2000. The topical calcineurin inhibitors tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream are approved for treatment of atopic dermatitis in the United States.

AB - Topical calcineurin inhibitors are a treatment option for individuals with certain limited manifestations of psoriasis. While these immunomodulatory drugs were initially developed for preventing organ rejection in transplant patients, they have quickly become a mainstay of off-label treatment for psoriasis since their clinical introduction in topical formulation in 2000. The topical calcineurin inhibitors tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream are approved for treatment of atopic dermatitis in the United States.

UR - https://www.scopus.com/pages/publications/85123143988

M3 - Chapter

AN - SCOPUS:85123143988

SN - 9781420088601

SP - 83

EP - 90

BT - Mild-to-Moderate Psoriasis, Second Edition

PB - CRC Press

ER -

Topical calcineurin inhibitors

Abstract

Fingerprint

Cite this